AstraZeneca cancer drug doesn’t show survival benefit

AstraZeneca Plc said its treatment for metastatic colorectal cancer, Recentin (cediranib), showed no improvement in overall survival in a Phase 3 trial, the second of two pivotal studies for this indication. A regulatory filing will not be made.